Patent cliffs aren’t just a legal event—they’re a pricing event.
When a blockbuster’s exclusivity window ends, the market doesn’t wait for your forecast model to catch up. Generic and biosimilar entrants arrive, payers reprice, formularies shift, and…

Post-approval is where the real IP battle begins.
Most teams obsess over pre-approval filings—patentability, exclusivity timelines, and the “big” Orange Book moments. But the risk curve doesn’t flatten after approval. It steepens. Once a drug is on t…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma companies don’t lose exclusivity only because patents expire. They lose it because the strategy around those patents is too slow, too narrow—or too risky.
In today’s environment, “defend exclusivity” isn’t a single legal action. It’s a coordinat…

From Humira to Keytruda: The Blueprint for Surviving the “Composition-of-Matter Cliff”
The composition-of-matter cliff isn’t a metaphor—it’s a calendar. One day, a blockbuster’s patent wall is still standing. The next, the wall starts to crumble, and t…

Pharma’s “patent cliff” isn’t just about expiring patents—it’s about how you write the claims.
For years, the industry has treated the patent cliff like a calendar problem: a fixed date, a predictable drop in exclusivity, a wave of generic competitio…

The patent dance isn’t a metaphor—it’s a timeline.
Before a single lawsuit is filed, biosimilar developers are already in a high-stakes choreography: patent listings, notice letters, “dancing” around exclusivity, and strategic decisions that can make…

Drug patent cliffs are coming—and the winners won’t just watch them. They’ll predict them.
If you’re in pharma, biotech, or legal strategy, you already know the pattern: patents don’t “expire” in a vacuum. They trigger litigation, settlement negotiatio…

Patent thickets aren’t just a legal inconvenience—they’re a market design problem. And if you’re a biotech, generic, or investor trying to navigate drug launches, the real question isn’t “Can we file?” It’s “Can we win the timing, the economics, and th…

Blockbuster drugs don’t just have patents—they have recipes. And if you’re trying to design around them, the real battleground is often formulation.
In the generic and competitive design-around world, the instinct is to focus on the headline claims: ac…